mmune thrombocytopenia (ITP) is an acquired autoimmune condition whereby autoantibodies against platelets lead to increased platelet clearance, suppression of megakaryocytopoiesis, and subsequent thrombocytopenia.1,2 ITP is associated with increased bleeding risk, and the primary goal of therapy is to prevent clinically significant bleeding. Steroids, and in some cases intravenous immunoglobulin, are recommended first-line therapies.3 However, many patients relapse and alternative therapies including splenectomy, rituximab, and thrombopoietin (TPO) receptor agonists are available for second-line treatment.